"enzalutamide" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "benzamide",
        "3": "-lutamide",
        "alt1": "(b)enza(mide)",
        "t2": "nonsteroid antiandrogen"
      },
      "expansion": "(b)enza(mide) + -lutamide (“nonsteroid antiandrogen”)",
      "name": "af"
    }
  ],
  "etymology_text": "From (b)enza(mide) + -lutamide (“nonsteroid antiandrogen”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "enzalutamide (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -lutamide",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Fundamental"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 July 16, “Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor”, in PLOS ONE, →DOI",
          "text": "Abiraterone and enzalutamide are newly approved drugs for CRPC patients; although, patients will still eventually relapse and the overall survival is prolonged only ~4–5 months after treatment with the AR signaling becoming active in most of these relapsed tumors.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A synthetic, non-steroidal pure antiandrogen developed for the treatment of metastatic castration-resistant prostate cancer."
      ],
      "id": "en-enzalutamide-en-noun-94i~7GXH",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "synthetic",
          "synthetic"
        ],
        [
          "non-steroidal",
          "non-steroidal"
        ],
        [
          "antiandrogen",
          "antiandrogen"
        ],
        [
          "metastatic",
          "metastatic"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A synthetic, non-steroidal pure antiandrogen developed for the treatment of metastatic castration-resistant prostate cancer."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "enzalutamide"
      ]
    }
  ],
  "word": "enzalutamide"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "benzamide",
        "3": "-lutamide",
        "alt1": "(b)enza(mide)",
        "t2": "nonsteroid antiandrogen"
      },
      "expansion": "(b)enza(mide) + -lutamide (“nonsteroid antiandrogen”)",
      "name": "af"
    }
  ],
  "etymology_text": "From (b)enza(mide) + -lutamide (“nonsteroid antiandrogen”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "enzalutamide (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms suffixed with -lutamide",
        "English terms with quotations",
        "English uncountable nouns",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2015 July 16, “Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor”, in PLOS ONE, →DOI",
          "text": "Abiraterone and enzalutamide are newly approved drugs for CRPC patients; although, patients will still eventually relapse and the overall survival is prolonged only ~4–5 months after treatment with the AR signaling becoming active in most of these relapsed tumors.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A synthetic, non-steroidal pure antiandrogen developed for the treatment of metastatic castration-resistant prostate cancer."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "synthetic",
          "synthetic"
        ],
        [
          "non-steroidal",
          "non-steroidal"
        ],
        [
          "antiandrogen",
          "antiandrogen"
        ],
        [
          "metastatic",
          "metastatic"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A synthetic, non-steroidal pure antiandrogen developed for the treatment of metastatic castration-resistant prostate cancer."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "enzalutamide"
      ]
    }
  ],
  "word": "enzalutamide"
}